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Background: Diabetic nephropathy is an emergent issue in China with increase in patients with type II diabetes.
There are several successful Chinese herbal products for the treatment of patients with diabetic nephropathy in
China. However, the mechanisms mediating the biological activity of these products are still unclear. Podocalyxin is
a sialoprotein critical to maintaining integrity of filtration function of glomerulus.
Methods: By employing streptozotocin-induced diabetic rats and a Chinese herb formulation (Yishen capsule), we
examined the regulation of podocalyxin expression in the kidney by Yishen capsule through immunofluorescent
staining and reverse transcriptase polymerase chain reaction.
Results: After injection of STZ, there were significant increase in both blood glucose and urinary protein. Serum
creatinine and BUN were also increased in rats with injection of STZ. Moreover, expression of podocalyxin in the
glomerulus was gradually reduced after injection of STZ. There was also a loss of podocyte foot processes in the
glomerular basement membrane. However, Yishen capsule or benazepril was able to restore the expression of
podocalyxin and podocyte foot processes in the kidney. Although Yishen capsule could reduce urinary protein
level, it has little effect on blood glucose level in the rats injected with STZ.
Conclusions: Yishen capsule could attenuate the loss of podocalyxin in the glomerulus of rats injected with STZ.Background
Recent investigation revealed that glomerular epithelial
cells or podocytes are the main cell type involved in the
development of diabetic nephropathy, which is one of
the most important microvascular complications associ-
ated with type 2 diabetic patients [1]. Diabetic nephropa-
thy refers to a spectrum of renal diseases in diabetic
patients from microalbuminuria to macroalbuminuria
and progressive decline in glomerular filtration rate [2].
Moreover, diabetic nephropathy is the most common
cause of the end-stage of renal disease (ESRD), which is
about 40% of patients receiving renal replacement
therapy in Asia [3]. Pathological changes of kidney in
diabetic nephropathy include the thickness of glomerular* Correspondence: fja3455001@126.com
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reproduction in any medium, provided the orbasement membranes and progressive accumulation of
extracellular matrix components, especially the change
of podocytes’ ultra-structure and function.
Podocytes are specialized cells located in the glomerular
basement. Interaction between podocyte foot processes
controls the glomerular filtration. There are several
proteins on podocyte membrane that are important in
regulation of the glomerular filtration such as nephrin,
podocin and podocalyxin [4,5]. Podocalyxin is an integral
membrane protein on the foot processes of kidney
podocytes [6]. It is a sialoprotein contributing to the nega-
tive charge of glomerular membrane. Knockout podo-
calyxin in mice resulted in early death after birth due to
the failure of podocytes to develop foot processes [7].
Regulation of podocalyxin in the developing kidney is
mediated by transcription factors - Wilms’ tumor suppres-
sor protein (WT1) and Sp1 [8,9]. However, regulation of
podocalyxin in adult kidney remains to be investigated.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Fang et al. BMC Complementary and Alternative Medicine 2013, 13:76 Page 2 of 10
http://www.biomedcentral.com/1472-6882/13/76Traditional Chinese medicine has been widely used in
China for the treatment of diabetes and diabetic compli-
cations. Several studies reported that Chinese herbal
medicines were used to improve conditions of patients
with diabetic nephropathy [10] and it becomes more
promising in the treatment of diabetic nephropathy [11].
From our clinical experience, we also developed a for-
mulation for patients with diabetic nephropathy, which
is named as Yishen capsule. Yishen capsule consists of
five Chinese herbs (Astragalus menbranaceus, Angelica
sinensis, Euryale ferox, Alisma orientale, and Rhodiola
rosea). Astragalus membranaceus and angelica sinensis
have been shown to regulate immune and oxidative
system [12]. In addition astragalus membranaceus has
been shown to improve patients’ proteinuria with idio-
pathic membranous nephropathy [13,14]. Euryale ferox
and alisma orientale also have antioxidative activity
[15,16]. Salidroside from rhodiola rosea has anti-inflam-
matory activity by inhibiting production of tumor
necrosis factor alpha and interleukin-6 [17]. Clinical
observation of this formulation revealed that it could
reduce proteinuria, protect renal function, and delay
progression of early diabetic nephropathy [18]. However,
the molecular and cellular mechanisms of Yishen cap-
sule for the treatment of diabetic nephropathy still
remain unclear. Therefore, in the current study, we
employs diabetic nephropathy model to investigate the
effects of Yishen capsule on proteinuria, glomerular
filtration and podocalyxin expression in the kidney.Methods
Materials: streptozotocin (STZ) and other chemical
reagents were purchased from Sigma Co. (St. Louis, MO.
USA). Rabbit anti-rat podocalyxin polyclonal antibody
and FITC conjugated goat anti-rabbit IgG polyclonal anti-
body were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA USA). Hoechst-33258 and Benazepril
hydrochloride were purchased from Biyuntian (Biyuntian
Biotechnology Co, Shanghai, CN) and Novartis pharma-
ceutical (Novartis pharmaceutical Inc., Beijing, China)
respectively.
Components of Yishen capsule: Yishen capsule was
prepared by the Department of Pharmacy of the First
Affiliated Hospital of the Shanxi Medical University. It
consists of Astragalus membranaceus, Angelica sinensis,
Euryale ferox, Alisma orientale, Rhodiola rosea in ratio
of 3:2:3:2:1. These herbs were boiled in water for 1 hour
three times. The decoctions were combined and filtered
through 3 M membranes. The decoction was then con-
centrated through vacuum evaporation to density of
1.20-1.24 at 70°C. The concentrated decoction was
further spray-dried to particle, which was then used to
fill capsule.Streptozotocin (STZ) induced model of diabetic ne-
phropathy: 48 Wistar rats weighing from 230-250 gram
were purchased from the Experimental Animal Centre
of the Shanxi Medical University. After one week, rats
were randomly divided into the following groups: 1)
normal control group (8 rats), 2) STZ diabetic group
treated with saline (24 rats), 3) STZ diabetic group
treated with Yishen capsule (8 rats) and 4) diabetic
group treated with benazepril (8 rats). Rats in normal
control group were treated with sham operation and
injection of 10 mM sodium citrate buffer pH 4.5 once
intraperitoneally one week after sham operation. Dia-
betic groups were treated with right uninephrectomy
follow by single intraperitoneal injection of 35 mg/kg
STZ in 10 mM sodium citrate buffer pH 4.5 one week
after uninephrectomy. After one week of STZ injection,
blood glucose level was examined with tail blood. When
the blood glucose level reached 16.7 mmol/L, rats were
confirmed to be at diabetic state. For group 2, rats were
sacrificed at 0, 4 and 12 weeks after STZ injection with
8 rats in each time point. Normal saline, Yishen capsule
(625 mg/kg/day) and benazepril (3.125 mg/kg/day) were
gavaged to rats in each group once every day for 12 weeks
respectively except for group 2 where some rats were
sacrificed at 0 and 4 weeks after STZ. The dose used in
the experiment was converted according to clinical dose
in patients which is 100 mg/kg/day for Yishen capsule and
0.5 mg/kg/day for benazepril. In addition, previous studies
also indicated that 625 mg/kg/day of Yishen capsule were
efficient to regulate podocytes [19]. This study was
approved by the Ethics Committee of the Shanxi Medical
University in accordance with the Guideline for the Care
and Use of Laboratory Animals.
Proteinuria: Twenty-four hours urinary samples were
collected from rats in metabolic cages without restriction
of water intake. Urines were collected at the end of 2, 4, 6,
8 and 12 weeks after STZ injection. After collection, urine
volume was recorded and 4 ml of urine were centrifuged
at 2,000 rpm for 10 minute. The supernatant were col-
lected and kept at -20°C until protein determination,
which was performed by the Bradford method [20].
Serum urine nitrogen (BUN) and creatinine (Cre)
determination: At the end of experiment, blood samples
(3 ml) were removed from the heart and rats were
sacrificed. Blood were left at room temperature for
1 hour and then at 4°C for 6 hours. Blood samples were
then centrifuged at 2,500 rpm for 15 minutes at 4°C.
The supernatant was then stored at -20°C until BUN
and Cre were determined by an automatic clinical chem-
istry analyzer (COBAS INTEGRAW 800 Roche).
Kidney histological examination: The kidneys were
collected at the end of experiment. Part of the kidney
was fixed in 10% neutral buffered formalin and embed-
ded in paraffin. Sections about 2-3 μm thick were cut
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by xylene. The sections were then subjected to standard
Periodic acid-Schiff (PAS) staining and were observed
under light microscopy with investigators blinded to
group identity.
Electron microscope analysis of the kidney podocytes
foot processes: Part of the kidney was fixed in 2.5%
glutaraldehyde for 2 hours and washed with PBS three
times. Tissues were fixed in 10% osmium tetroxide for
2 hours and embedded in Epon812. After ultracut,
section was stained with lead citrate and ultrastructure
of the kidney was observed under Hitachi H-600
electron microscope (Hitachi Company, Japan) at magni-
fication of 36,000X. Thirty visions were observed for
each section to insure that one hundred vision fields
were obtained for each rat.
Immunofluorescent examination of podocalyxin in the
kidney: Part of the kidney was snap-frozen in n-hexane
cooled to -70°C and then 4 μm-thick sections were cut
with a cryostat (Leica, CM1850, German). After the
sections were mounted on glass slide and washed three
times with PBS, the sections were incubated with 3%
BSA for 30 minutes to block non-specific binding. The
primary antibody against podocalyxin was incubated
with the kidney section overnight at 4°C. The PBS was
used for negative control. After washing three times with
PBS of 10 minutes each time, 50-100 μl of FITC conju-
gated goat anti-rabbit secondary antibody will be incu-
bated with the section for 1 hour under the dark
condition. The sections were then dried, sealed and
stored at 4°C until observation under fluorescence mi-
croscopy (Optima 6.5, Media Cybernetics Inc. Silver
Spring, MD, USA) with 100X objective. The densities of
flurorescence were determined by computer analysis
with Image-Pro Plus 5.0 (Media Cybernetics, USA).
Reverse transcriptase-polymerase chain reaction (RT-
PCR): Total RNA from kidney was isolated by using
TRIzol reagent (Invitrogen, USA) according to the ma-
nufacturer's protocol. Two μg RNA was employed for
the first strand cDNA synthesis by using moloney
murine leukemia virus reverse transcriptase. PCR ampli-
fication was performed using a thermocycler (Bio-Rad
Laboratory, USA) by the following steps: denaturing at
94°C for 5 min followed by 35 cycles of denaturing at
94°C for 30 seconds, annealing for 30 seconds at
temperature 52°C for podocalyxin and 51°C for GAPDH,
and extending at 72°C for 45 seconds. PCR was ended
after elongation at 72°C for 10 min. The sequences of
primers for podocalyxin are sense strand = ACC GGT
CCT TAA TTG GTT CC and antisense strand = CCT
TTG GCA GTT AGG AGC TG. Product length is 201
base pair. Primers sequences for GAPDH are sense
strand = TGA ACG GGA AGC TCA CTG G and anti-
sense strand = TCC ACC ACC CTG TTG CTG TA.Product length is 307 base pair. Densities of the bands
were quantified using the Quantity One software (Bio-rad,
USA), and results were represented as ratio of podocalyxin
to GAPDH.
Statistical analysis: The data were represented as mean ±
standard deviation (SD). Differences between control and
treatment groups were analyzed by the ANOVA and
Fisher's PLSD test as Post hoc test using the SPSS10.0
statistical analysis software. P value of less than 0.05 was
considered as statistical significance.
Results
Blood glucose and microalbuminuria in STZ induced
diabetic rats
To examine early change of the kidney in diabetic
nephropathy, we employed STZ induced diabetic model
and examined the blood glucose and urinary albumin
level at 2, 4, 6, 8 and 12 weeks after injection of STZ. As
shown in Figure 1A, rats without injection of STZ had a
normal blood glucose level around 5 mmol/L while rats
with STZ injection had higher blood glucose level
around 20 mmol/L. With treatment of Yishen capsule or
benazepril, there was no statistically significant reduction
of blood glucose level compared to that of STZ treat-
ment alone. In addition, we measured 24 hours albumin
in the urines of these rats and found that except normal
control group, albumin content in the urines of all other
groups was elevated two weeks after STZ injection
(Figure 1B). Rats in STZ group showed gradual in-
creased microalbuminuria from 2 weeks to 12 weeks
after STZ injection. Although rats treated with Yishen
capsule or benazepril also showed gradual increased
microalbuminuria, the amount of albumin in the urines
of these rats was significantly lower than that of rats in
STZ group at 4, 6, 8, 10 and 12 weeks after STZ injec-
tion respectively.
Expression of podocalyxin in STZ induced diabetic rats
We then sacrificed rats at 0, 4, and 12 weeks after STZ
injection for examination of kidney histology and the
expression of podocalyxin. As shown in Figure 2, glom-
erulus of the kidney at 12 weeks after STZ injection
shows increased space within glomerulus. The expres-
sion of podocalyxin was documented by both immuno-
fluorescent histology and RT-PCR analysis. As shown in
Figure 2A, there was a gradual reduction of fluorescent
intensity after STZ injection from 0 to 4 weeks to
12 weeks. The intensity of podocalyxin fluorescence at
12 weeks after STZ injection is only about one third of
that before STZ injection. RT-PCR also documented a
gradual reduction of podocalyxin mRNA level after STZ
injection (Figure 2B). The amount of podocalyxin
mRNA in the kidney at 12 weeks after STZ injection is
also about one third of that before STZ injection.
Figure 1 Glucose and urinary albumin levels after STZ injection in rats. After rats were injected with STZ, blood glucose level and urinary
albumin level were determined at different time intervals as indicated. Blood glucose levels were significantly increased in rats with injection of
STZ and treatments of Yishen or benazepril. Urinary protein was also gradually increased in rats with STZ injection. However, both Yishen and
benazepril treatments were able to reduce the amount of protein in the urine but were not able to bring protein content back to its normal
level. Data are expressed as mean ± SD from eight rats. * indicates p < 0.05 as compared to normal control group.
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induced diabetic rats
After successful documentation of diabetes in rats and
expression of podocalyxin in the kidney after STZ
injection, we further examined the effects of Yishen
capsule on STZ induced diabetes and expression of
podocalyxin in the kidney. As shown in Figure 3, there
was a significant increase in both Scr and BUN in the
blood of rats in STZ group as compared to that of rats
in normal group at 12 weeks after STZ injection. More-
over, treatment of Yishen capsule or benazepril signifi-
cantly reduced both Scr and BUN in these rats.
Regulation of podocalyxin expression by Yishen capsule
or benazepril was documented at 12 weeks after STZ
injection by immunofluorescent histology and RT-PCR
analysis (Figure 4). Both Yishen capsule and benazepril
significantly restored the expression of podocalyxin
protein and mRNA in the kidney as documented by
immunofluorescence (Figure 4A) and RT-PCR analyses
(Figure 4B) respectively. Although the level of podo-
calyxin in Yishen treated rats was lower than that in
benazepril treated rats, there was no statistically signifi-
cant between these groups. Furthermore, we examined
ultrastructure of the glomerular basement membrane.
As shown in Figure 5, podocyte foot processes was
inter-connected to each other in the glomerular base-
ment membrane of normal kidney (Figure 5A). However,
STZ treatment significantly reduced podocyte foot pro-
cesses and there was a lot of space between basement
membrane (Figure 5B). Moreover, treatment of eitherYishen capsule or benazepril restored podocyte foot
processes almost back to normal level (Figure 5C & 5D).
Discussion
Development of diabetic nephropathy is a complicated
process, which involves in several factors such as
glomerular mesangial cells and podocytes. Podocyte
injury has been considered as one of the most important
factors in diabetic nephropathy [21,22]. Several medi-
cines that protect podocyte injury usually have a role in
prevention of development of diabetic nephropathy.
These medications are either conventional drugs or
some herbs from traditional Chinese medicine [10,23].
In the current report, we employed Yishen capsule that
have been documented to reduce progression of diabetic
nephropathy in patients with type II diabetes [18], to in-
vestigate their mechanism of prevention of diabetic ne-
phropathy. Yishen capsule includes an herb (Astragalus
membranaceus), which is known to treat proteinuria in
patients with diabetic nephropathy. However, molecular
and cellular mechanism of these herbs to attenuate the
development and progression of diabetic nephropathy
are still unclear. Our study reveals that Chinese herbs
could modulate the expression of podocalyxin in the
kidney of streptozotocin-induced diabetic rats.
Podocalyxin is one of the major negatively charged
glomerular proteins in the glomerular basement mem-
brane. It located on the surface of podocytes that faces
the urinary space. Podocalyxin also plays an important
role in maintenance of the intricate glomerular podocyte
Figure 2 Expression of podocalyxin in the kidney after STZ injection in rats. Kidney histology and expression of podocalyxin were
documented with HE staining, immunofluorescent staining of podocalyxin and RT-PCR analysis of podocalyxin mRNA respectively. As shown in
panel A, glomerulus was damaged and podocalyxin fluorescent intensity was reduced (magnification x400). The expression of podocalyxin was
gradually reduced from 0 to 12 weeks after STZ injection. The expression of podocalyxin was further documented by RT-PCR analysis of
podocalyxin mRNA as displayed in panel B. Podocalyxin level at 12 weeks after STZ injection was about one third of normal value. Data are
expressed as mean ± SD from eight rats. * indicates p < 0.05 as compared to normal control group.
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Figure 3 Effect of Yishen capsule on serum creatinine and BUN levels in STZ induced diabetic rats. Rat blood was prepared from different
groups as indicated. Serum creatinine and BUN levels were determined as described in the materials and methods. Panel A displays the effect of
Yishen capsule on serum creatinine in different groups. Panel B shows the effect of Yishen capsule on BUN levels in different groups. Data are
expressed as mean ± SD from eight rats. * indicates p < 0.05 as compared to normal control group.
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calyxin changed in numerous human diseases and ani-
mal models of glomerular malfunction, such as diabetic
nephropathy, puromycin aminonucleoside nephrosis and
protamine sulfate perfusion. In these conditions, podo-
calyxin’s negative charge is neutralized, foot process
architecture is disrupted, and slit diaphragms are
displaced or completely replaced by leaky, discontinuous
junctions [24]. Podocalyxin-knockout mice shew that
podocalyxin maintains the unique podocyte morphology
because in these mice, there were fewer major processes,
and lack foot processes and slit diaphragms [7]. In our
current study, we also observed similar morphological
changes in the kidney of STZ-induced diabetic rats
showing lack of foot processes and slit diaphragms.However, treatment with Yishen capsule corrected these
defects. These modifications of the glomerulus were
similar to those of benazepril. These changes could be
due to regulation of podocalyxin expression by either
Yishen capsule or benazepril as demonstrated in the
current study.
The Yishen capsule is a formulation of traditional
Chinese herbs created by Dr. Fang in 1995, which has
been employed to treat patients with chronic kidney dis-
ease [25,26]. Among these herbs, astragalus and angelica
have been demonstrated to protect heart and brain
injury due to ischemia/reperfusion. Moreover, astragalus
and angelica also promote tubular cell proliferation
during renal ischemia/reperfusion injury. Although the
mechanism involved in protection of ischemia/reper-
Figure 4 Effect of Yishen capsule on the expression of podocalyxin in the kidney of STZ induced diabetic rats. The regulation of
podocalyxin in the glomerulus is displayed in panel A (podocalyxin fluorescence) and panel B (RT-PCR). Both Yishen capsule and benazepril were
able to restore expression of podocalyxin in the glomerulus of rats with STZ injection. However, podocalyxin levels in Yishen capsule and/or
benazepril treatment groups are still lower than that of normal group. Data are expressed as mean ± SD from eight rats. * indicates p < 0.05 as
compared to normal control group.
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further investigation, the components of astragalus such
as flavone, saponin and polysaccharide can inhibit lipid
peroxidation and enhance anti-oxidative activity of cells
[27,28]. Furthermore, astragalus induced complete remis-
sion of idiopathic membranous nephropathy [13,14]. Inaddition, angelica was able to reduce intracellular Ca2+
overload and one of its components – ferulic acid was also
able to reduce production of superoxide in hepatocytes
and prevent injury of lipid membrane after ischemia/re-
perfusion [29]. Other herbs in the formulation include
euryale ferox, alisma orientale and rhodiola rosea. Both
Figure 5 Electron microscopy examination of the glomerular basement membrane in the kidney of rats. Sections of kidney from different
groups were analyzed with electron microscope (magnification x36,000). There was a significant reduction of podocyte foot processes in STZ
injection groups. Panel A represents the kidney from normal rats. Panel B shows the kidney from STZ injected rats. Panel C and panel D display
the kidney tissues from STZ injected rats with treatments of Yishen capsule or benazepril respectively.
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activity [15,16] while a component of rhodiola rosea
(salidroside) could inhibit inflammatory cytokines produc-
tion such as tumor necrosis factor alpha and interleukin-6
[17]. Therefore, Yishen capsule has anti-oxidative and
anti-inflammatory function.
Natural herb products as complementary therapies for
chronic kidney disease have been widely investigated.
Most of these therapies were focused on recovery of
kidney function after ischemia/reperfusion injury of the
kidney. For example, Cordyceps sinesis (dongchongxia-
cao), which is a blade-shaped fungus derived from larvae
of Lepidoptera found at high altitude [30], has been used
in patients with chronic kidney disease and animal
model of kidney ischemia/reperfusion [31]. It has been
documented that Cordyceps sinesi had strong anti-
oxidative activity and could improve renal function after
kidney ischemia/reperfusion injury. Moreover this func-
tion might be related to its regulation of inflammatory
cytokines such as chemoatractant protein-1 and tumor
necrosis factor-α [32]. Other Chinese herbs such as
Rheum palmatum (chishao) [33], Salviae miltiorrhizae
(danshen) [34], Astragalus membranaceus (huangqi) and
Angelica sinensis (dangui) [35] could also have anti-oxidative activity and help to recover kidney function in
ischemia/reperfusion injury or nephrotic syndrome. More-
over, a traditional Chinese herbal formula - Sairei-to
(chailingtang) has been shown to have protective effects
on kidney injury due to its suppression of mesangial cell
proliferation [36]. Therefore, not only single herb but also
combination of herbs has renal protective property. More-
over, a Korean herbal combination (KIOM-79) was able to
reduce advance glycation end product accumulation in
diabetic rats [37]. This finding indicates that herbal
products might also protect kidney injury in patients with
diabetes. The current finding in our study also strongly
supports that herbal product might reduce podocalyxin
expression to prevent diabetic induced kidney injury.Conclusions
Podocalyxin expression was significantly reduced in the
kidney of STZ induced diabetes. A unique formulation of
Chinese herbs (Yishen capsule) used in our hospital could
restore the expression of podocalyxin in the kidney
induced by STZ and improve microalbuminuria in the
rats. However, this formulation was not able to reduce
blood glucose level in STZ induced rats.
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